Drug Confirmation Test

The Panel 1 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine and verifies positive findings with advanced confirmatory testing. This two-step process improves accuracy by reducing the chance of false positives, making it valuable for clinical, workplace, or monitoring settings. The combination of broad screening and confirmation ensures reliable assessment of recent substance exposure.

The Panel 6 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine via immunoassay screening and then validates positive findings with confirmatory testing. This two-step method enhances result reliability by reducing false positives, providing a trustworthy overview of substance exposure suited for clinical, monitoring, or workplace settings.

The Alcohol Urine Drug Screen with Confirmation detects and confirms the presence of ethyl glucuronide (EtG), a direct metabolite of alcohol, in urine samples. This test is designed to identify recent alcohol use and verify initial screening results with confirmatory analysis, providing reliable and accurate information for monitoring purposes in clinical, legal, and treatment settings.

The Amphetamines Urine Drug Screen with Confirmation combines initial screening and confirmatory testing to detect and verify the presence of amphetamines in urine. This method delivers both sensitivity and specificity, ensuring positive results are validated. Ideal for clinical, legal, or monitoring settings, it supports reliable reporting of amphetamine use.

The Amphetamines Urine Drug Screen with Confirmation and D/L Isomers first screens for amphetamine compounds, then applies confirmatory testing that distinguishes D- and L-methamphetamine isomers. This test combines detection, verification, and isomer differentiation to offer more precise insight in clinical, legal, or monitoring settings.

The Barbiturates Urine Drug Screen with Confirmation performs an initial immunoassay screening for barbiturates and then confirms positives using mass spectrometry. It verifies the presence of barbiturate drugs like phenobarbital, pentobarbital, secobarbital, and more. Designed for clinical, legal, or treatment monitoring, it delivers both detection and validation for greater confidence in results.

The Base Panel Urine Drug Screen with Confirmation combines an initial multi-drug immunoassay screen with confirmatory testing to validate positive findings. It detects common substances across multiple drug classes in urine, then uses advanced analysis to confirm the presence of specific analytes. This dual approach boosts accuracy and confidence in results for clinical or monitoring settings.

The Benzodiazepines Urine Drug Screen with Confirmation performs an initial screening for benzodiazepine compounds in urine, followed by confirmatory testing to validate positive results. This process ensures reliable identification of drugs like diazepam, lorazepam, or alprazolam in clinical or monitoring settings, adding confidence and specificity to benzodiazepine detection.

The Buprenorphine and Naloxone Urine Drug Screen with Confirmation begins with a screening test for buprenorphine and its metabolites (including naloxone) in urine, then validates positive findings using confirmatory methods. This combined approach balances sensitivity and specificity, helping clinicians, treatment programs, or monitoring services to reliably verify medication-assisted therapy adherence.

The Cocaine Urine Drug Screen with Confirmation combines an initial immunoassay screen for cocaine metabolites with confirmatory testing to verify positive findings. This two-step approach ensures both detection and validation of cocaine use in urine, improving specificity and confidence of results for clinical, legal, or monitoring applications.

The Fentanyl Urine Drug Screen with Confirmation performs an initial immunoassay screening for fentanyl and then applies confirmatory testing (e.g. mass spectrometry) to verify positive results. This two-step process reduces false positives and ensures specificity in detecting fentanyl use in urine for clinical or monitoring programs.

The Heroin Urine Drug Screen with Confirmation begins with an immunoassay screen for heroin metabolites (such as 6-monoacetylmorphine), then reflexes positives to mass spectrometry confirmation. This two-step approach ensures both sensitivity and specificity, validating the presence of heroin use in urine and reducing false positives for clinical or monitoring purposes.

The Marijuana Urine Drug Screen with Confirmation performs an initial immunoassay screen for THC metabolites (such as THC-COOH) in urine, followed by confirmatory testing to validate any positive findings. This two-step testing approach ensures both sensitivity and specificity, providing reliable confirmation of cannabis use in clinical, monitoring, or compliance settings.

The MDMA/MDA Urine Drug Screen with Confirmation begins with a broad immunoassay screen for MDMA and its metabolite MDA, then applies confirmatory testing (e.g. mass spectrometry) to validate positives. This two-step approach enhances specificity and ensures that detected substances are correctly identified, providing reliable verification of ecstasy (MDMA/MDA) use in clinical or monitoring settings.

The Methadone Urine Drug Screen with Confirmation begins with immunoassay screening for methadone metabolites, then applies confirmatory analysis to verify positive findings. This two-step approach enhances specificity and reduces false positives, providing reliable validation of methadone use in urine for clinical, compliance, or monitoring purposes.

The Mitragynine Urine Drug Screen with Confirmation screens for the kratom alkaloid mitragynine in urine, then applies confirmatory testing to validate positive findings. This two-step process enhances accuracy and specificity, helping clinicians and monitoring programs reliably identify kratom use with both detection and verification of mitragynine presence.

The Opiates Urine Drug Screen with Confirmation begins with immunoassay screening for opiate compounds (such as morphine, codeine, hydrocodone), then validates positive results using confirmatory methods. This two-step process ensures specificity and reduces false positives, delivering reliable confirmation of opiate detection in urine for clinical, legal, or monitoring settings.

The Oxycodone Urine Drug Screen with Confirmation begins with an immunoassay screen for oxycodone and its metabolites in urine, then uses confirmatory testing (e.g. mass spectrometry) to validate positive results. This two-step process enhances specificity and reduces false positives, offering reliable confirmation of oxycodone exposure in clinical and monitoring settings.

The Panel 3 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine through immunoassay screening, with positive results verified by advanced confirmatory methods. This two-step process enhances accuracy by minimizing false positives and provides reliable insight into substance exposure. It is suited for clinical, workplace, and monitoring applications requiring dependable results.

The Panel 4 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine through immunoassay screening, then verifies positive findings using confirmatory analysis. This two-step process enhances specificity and reduces false positives, providing dependable insight into substance exposure for clinical, monitoring, or workplace applications.

The Panel 5 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine via immunoassay screening and validates positive findings through confirmatory analysis. This dual-step approach reduces false positives and improves specificity, offering a more trustworthy evaluation of substance exposure in clinical, monitoring, or workplace contexts.

The Panel 5 Urine Drug Screen with Confirmation and D/L Isomers detects multiple commonly abused drugs in urine via immunoassay screening and verifies positive findings. It further differentiates D- and L-isomer forms of amphetamines to improve specificity and interpretive clarity. This multi-step analysis supports accurate results in clinical, workplace, and monitoring settings.

The Panel 7 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine via immunoassay screening and then validates positive results through confirmatory testing. This two-step approach increases specificity by reducing false positives, providing dependable insight into exposure to an extended panel of substances in clinical, monitoring, or workplace settings.

The Panel 8 Urine Drug Screen with Confirmation detects multiple commonly abused drugs in urine through immunoassay screening and validates positive results using confirmatory analysis. This two-step method enhances specificity and reduces false positives, providing reliable insight into substance exposure across a broader panel of substances in clinical, workplace, and monitoring environments.